+44 20 8123 2220
info@marketpublishers.com

Neurofibromatoses Type II - Pipeline Review, H1 2020

https://marketpublishers.com/r/NCE1D7236DBEN.html
Date: April 2020
Pages: 44
Price: US$ 2,000.00 (Single User License)
ID: NCE1D7236DBEN

Abstracts

Neurofibromatoses Type II - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Pipeline Review, H1 2020, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type II - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

II, Phase 0 and Discovery stages are 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type II (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type II (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type II - Overview
Neurofibromatoses Type II - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type II - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type II - Companies Involved in Therapeutics Development
AstraZeneca Plc
Beta Pharma Inc
BioXcel Corp
Plex Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Neurofibromatoses Type II - Drug Profiles
bortezomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-2282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

+44 20 8123 2220
info@marketpublishers.com

Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurofibromatoses Type II - Dormant Projects
Neurofibromatoses Type II - Product Development Milestones
Featured News & Press Releases
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Number of Products under Development for Neurofibromatoses Type II, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, H1 2020
Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, H1 2020
Neurofibromatoses Type II - Pipeline by BioXcel Corp, H1 2020
Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, H1 2020
Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Neurofibromatoses Type II - Dormant Projects, H1 2020

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neurofibromatoses Type II, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AstraZeneca Plc
Beta Pharma Inc
BioXcel Corp
Plex Pharmaceuticals Inc
Recursion Pharmaceuticals Inc

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Neurofibromatoses Type II - Pipeline Review, H1 2020
Product link: https://marketpublishers.com/r/NCE1D7236DBEN.html
Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NCE1D7236DBEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970